Supplemental Data
Files in this Data Supplement:
- Supplementary Figure S1 - Comparison of the differentially abundant proteins in the current study with the published pooled OPC proteome (Slebos et al, 2013).
- Supplementary Figure S2 - Prognostic effects of cortactin and proteomic sub-groups.
- Supplementary Table S1 - Clinico-pathological characteristics for each patient for tissue mass spectrometry studies.
- Supplementary Table S2 - Clinico-pathological characteristics for each patient for tissue IHC studies.
- Supplementary Table S3 - List of proteins identified in OPC tissues listed with number of peptides, number of spectra, number of adjusted spectra and sequence coverage.
- Supplementary Table S4 - Normalized abundance values of protein groups identified in OPCs.
- Supplementary Table S5 - List of peptides identified in OPC tissues listed with charge state, minimum and maximum expectation scores for X!Tandem, OMSSA, MyriMatch algorithms and number of spectra.
- Supplementary Table S6 - Proteins in the significantly over-represented KEGG Pathway and GO categories.
- Supplementary Table S7 - Combined list of protein groups identified in both OPC proteome studies.
- Supplementary Table S8 - Mutation, copy number, methylation and mRNA abundance differences in HPV+ vs. HPV- OPCs as per the TCGA Head and Neck Study mapped to differential protein groups in current study.
- Supplementary Table S9 - Univariate overall and disease-free survival analysis according to OPC cortactin protein levels.
- Supplementary Table S10 - Clinico-pathological characteristics according to cortactin levels and proteomic clusters.
- Supplementary Table S11 - Prognostic analysis of proteomic OPC sub-groups.
- Supplementary Table S12 - Prognostic analysis of proteomic OPC sub-groups stratified according to HPV status.